Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 69Neoplasms 20Neoplasm Metastasis 12Brain Neoplasms 4Stomach Neoplasms 2Recurrence 2Osteitis Deformans 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2HER2 Positive Metastatic Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER-2 Gene Amplification 1Glioma 1Glioblastoma 1Diarrhea 1Carcinoma 1Breast Diseases 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER-2 Gene Amplification × Lapatinib × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡